우울에 대한 Moclobemide(Aurorix) 의 임상적연구

• 영문명: A Clinical Study of Moclobemide(Aurorix) on Depression
• 발행기관: 대한신경정신의학회
• 저자명: 李定均
• 간행물 정보: 『신경정신의학』제33권 제2호, 444~452쪽, 전체 9쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 1994.03.30

영문 초록

The author has studied clinical effects of Moclobemide on depression. Moclobemide is a reversible monoamine oxidase inhibitor which predominently inhibits the A form of MAO. The results was as follows : 1) Sample size was 30(male 9, female 21), mean age 51.17 and diagnosis(ICD 9) was neurotic depression. 2) Moclobemide was administered 30—45mg/daily(100—150mgx tid) for 6 weeks and evaluated every 2 weeks. 3) Hamilton Depression Scale score of pretreatment was 26.13 and 2.37 at posttreatment. 4) Clinical global impression (CGI) were 4.03 (pretreatment), 3.30(after 2 weeks), 2.5 (after 4 weeks) and 1.90(after 6 weeks) respectively. 5) There were no significant differences in vital signs, blood chemistry and urinalysis. 6) Moclobemide is an recommendable antidepressant for clinical use.

목차

서 론

대상 및 방법

결 과

고 찰

결 론

참고문헌

키워드

Moclobemide Depression